@mannyjplays 12-week 'LOCK IN' peptide stack: BPC-157 + Retatrutide + CJC-1295/Ipamorelin
The 12-week "LOCK IN" peptide stack. These three peptides form a foundational base that can be expanded upon. However, starting research with just these compounds may lead to significant metabolic, physical, and cognitive changes. BPC-157 While BPC-157 is widely known for supporting injury recovery, it may also provide systemic support that enhances the effectiveness of other peptides. This is thought to occur through improved blood flow, multi-system healing (including muscles, tendons, gut, and brain), and increased nitric oxide production. Overall, BPC-157 may help create a more efficient internal environment for other compounds to function. Retatrutide (GLP-1/GIP/Glucagon "Triple Agonist") Retatrutide acts as a triple agonist, meaning it activates three different hormone receptors in the body: GLP-1 receptors (found in the brain, pancreas, and gastrointestinal tract): Activation may: Slow gastric emptying / Reduce appetite / Improve blood glucose regulation GIP receptors (distributed throughout the body): Activation may: Enhance insulin response / Improve nutrient utilization / Support fat metabolism Glucagon receptors (primarily in the liver, adipose tissue, and kidneys): Activation may: Increase energy expenditure / Promote fat breakdown Lastly, but not to be overlooked: CJC-1295 / Ipamorelin (No DAC) This combination includes two peptides that work synergistically: CJC-1295 stimulates the pituitary gland to increase natural growth hormone (GH) production. Ipamorelin promotes the release of GH without significantly triggering inhibitory pathways (such as somatostatin). Together, this blend may: Support fat loss (especially when combined with retatrutide) / Enhance muscle recovery and growth / Help maintain or improve lean body mass Together, these peptides are positioned as a foundational stack aimed at improving body composition, metabolic efficiency, and recovery.
A real attempt at a body-recomp stack. Retatrutide is the most effective weight-loss drug in the clinical pipeline, and CJC-1295/Ipamorelin is a well-established GH-releasing combo. But three things hold this back: no doses are disclosed, the BPC-157 'enhances other peptides via blood flow' framing is marketing on weak evidence, and retatrutide is an Eli Lilly trial drug not legally available outside studies, so any vendor-sourced retatrutide is gray-market diverted or unverifiable counterfeit. '12-week LOCK IN' is influencer-vibes around a stack that wants to be taken seriously.
| Goal | Score | Grade | Weight | Why |
|---|---|---|---|---|
| Longevity | — | Not targeted | — | No primary longevity mechanism. Sustained GH-axis stimulation in healthy adults is arguably anti-longevity per the IGF-1 and aging literature. |
| Cognition | — | Not targeted | — | No ingredient with a cognitive mechanism. The post claims 'cognitive changes' but doesn't substantiate. |
| Sleep & recovery | 73 | C | 20% | BPC-157 supports recovery and CJC-1295/Ipamorelin GH pulsing aligns with deep-sleep architecture when dosed pre-bed. Modest effects, dose-dependent. |
| Energy & metabolism | 79 | C+ | 30% | Retatrutide's triple agonism is genuinely metabolic-targeted. GH from CJC/Ipa adds modest lipolytic effect but can worsen insulin sensitivity at higher doses. |
| Body recomposition | 79 | C+ | 50% | Mechanism is real. Retatrutide Phase 2 data is exceptional and CJC/Ipa is established for fat loss and lean mass. But no doses, vendor sourcing concerns for retatrutide, and missing training/diet detail keep this off the B range. |
Ingredients (3)
BPC-157
- Dose
- unspecified
- Mechanism
- Pentadecapeptide derived from a gastric protein; preclinical evidence for angiogenesis, fibroblast migration, and growth factor signaling. The 'enhances other peptides via systemic blood flow' framing is enthusiast-circle theory, not literature.
- Take
- Common research-peptide protocols use 200–500mcg/day. The 'foundational base that improves how other peptides work' claim isn't supported by published evidence. It's a theory popular in peptide-influencer circles to justify always including BPC-157. The compound is reasonable for recovery in isolation, but the systemic-amplifier framing here is overreach.
Retatrutide
Retatrutide on peptidelist.org ↗
- Dose
- unspecified
- Mechanism
- GLP-1/GIP/glucagon triple-receptor agonist. Activates GLP-1 (appetite, gastric emptying, glucose regulation), GIP (insulin response, lipid metabolism), and glucagon (energy expenditure, lipolysis) receptors. Eli Lilly trial drug; Phase 2 data exceeded tirzepatide and semaglutide on bodyweight outcomes.
- Take
- Author doesn't state a dose. Phase 2 trials titrated up to 8–12mg/week subQ over a 24-week period, achieving ~24% bodyweight loss at 48 weeks. That's the most extraordinary body-recomp data in the clinical pipeline. The bigger problem: retatrutide is Phase 3 trial-stage, not FDA-approved. Legitimate access is essentially trial enrollment only. Anything sold as 'retatrutide' on the research-peptide market is diverted from trials or unverifiable synthesis, and counterfeit GLP-1-class drugs have been documented with off-target compounds.
CJC-1295 / Ipamorelin (No DAC)
- Dose
- unspecified
- Mechanism
- GH-releasing peptide combo. CJC-1295 (no DAC, short-acting GHRH analog) stimulates pituitary GH release via GHRH receptors. Ipamorelin is a selective GH secretagogue (ghrelin mimetic) that triggers GH without elevating cortisol or prolactin. Combined to produce pulsatile GH spikes.
- Take
- Standard enthusiast protocol is 100–300mcg of each, 1–3×/day, typically pre-bed and post-workout. 'No DAC' (no Drug Affinity Complex) means short half-life and a need for multiple daily doses. The rationale: pulsatile GH release that mimics endogenous secretion rather than sustained elevation. Real GH effects on body comp are dose-dependent and accompanied by water retention, joint discomfort, and insulin resistance at higher doses. The combo has been around 15+ years. Mechanism is real, magnitude is modest in healthy adults.
Risks & interactions
- Retatrutide is not legally available outside trials, and sourcing risk dominatescritical
Retatrutide is in Phase 3 trials with Eli Lilly and not FDA-approved. There is no legitimate supply chain for self-administration. Anything labeled 'retatrutide' from a research-peptide vendor is either trial diversion (rare, expensive, traceable) or unverifiable synthesis from an offshore lab. Counterfeit GLP-1-class drugs have been documented with off-target compounds including dangerous sympathomimetics. This isn't a sourcing concern on top of a legitimate compound. It's the central risk of the entire stack.
- GH-axis stimulation in healthy adultshigh
CJC-1295/Ipamorelin elevates GH and downstream IGF-1. In healthy adults, sustained IGF-1 elevation has known associations with insulin resistance, joint discomfort, fluid retention, and (long-term, at higher doses) cancer-progression concerns. The 'No DAC' / pulsatile dosing approach softens but doesn't eliminate these. Bloodwork (IGF-1, fasting glucose, HbA1c) is non-optional for any sustained protocol.
- No doses for any compound across a 12-week protocolhigh
Three peptides over 12 weeks with zero dose disclosure makes this stack not replicable, not titrable, and not evaluable. For a protocol involving a Phase-3 trial drug and a GH-axis intervention, this is the wrong level of detail to publish, even allowing for legal-cover ambiguity in 'research' marketing language.
- GLP-1/triple-agonist GI side effects under-discussedmedium
GLP-1-class drugs (and triple agonists especially) cause significant nausea, vomiting, and GI distress in 30%+ of users at therapeutic doses. The 'LOCK IN' framing skips this entirely. For a 12-week protocol, GI-driven dropout is the likely failure mode even before any safety concern. Slow titration and antiemetic protocols are standard in trial settings.
- 'Foundational base' BPC-157 framing is bro-sciencemedium
The post claims BPC-157 'creates a more efficient internal environment for other compounds to function.' This is a popular peptide-circle claim with no published mechanism or trial support. It functions to justify always-including BPC-157 alongside whatever else is being sold. Treat the claim as marketing, not pharmacology.
The Phase 2 data for retatrutide is real and remarkable. The supply chain isn't. Anything sold as 'retatrutide' on the research-peptide market is gray-market trial diversion or unverifiable counterfeit synthesis, and counterfeit GLP-1-class drugs have been documented with off-target compounds. Wait for FDA approval (expected late-decade). Until then, you don't actually know what you're injecting. The other two peptides can stand alone in the meantime.
Estimated cost
BPC-157 ~$30–60/mo and CJC-1295/Ipamorelin ~$100–200/mo at typical research-peptide vendor pricing. 'Retatrutide' is the variable. Vendor pricing ranges from ~$300/mo for low doses to $1500+/mo for higher, with the central caveat that it isn't legitimately available, so any 'retatrutide' purchase is paying for product whose identity isn't verifiable.